Broad Effectiveness: Study With Aripiprazole

Phase 3

Completed

• Conditions: Schizoaffective Disorder; Schizophrenia

• Registration Number: NCT00036361
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2002-05-08
• Study First Submitted QC: 2002-05-09
• Study First Posted: 2002-05-10
• Study Start: 2002-07
• Primary Completion: 2003-01
• Study Completion: 2003-01
• Status Verified: 2007-09
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 444

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Safety Assessments

Secondary Outcome Measures

Name	Time	Method
Safety Assessments

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Wallingford, Connecticut, United States